☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search category
Search here
Search here
Subscribe Now
Sanofi
Sanofi Reports the P-II Study Data of Frexalimab for the Treatment of Multiple Sclerosis
July 1, 2024
Sanofi Reports the P-II Study Data of Riliprubart to Treat Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
June 26, 2024
Sanofi Highlights the P-III (IMROZ) Study Data of Sarclisa for Newly Diagnosed Transplant-Ineligible Multiple Myeloma
June 4, 2024
Sanofi & Regeneron’s Dupixent Receives the CHMP’s Positive Opinion for Treating Chronic Obstructive Pulmonary Disease (COPD)
May 31, 2024
Sanofi Reports the US FDA’s sBLA Acceptance of Sarclisa to Treat Transplant-Ineligible Newly Diagnosed Multiple Myeloma
May 27, 2024
Sanofi Highlights Data from P-II Trial of Rilzabrutinib to Treat Moderate-to-Severe Asthma at ATS 2024
May 23, 2024
Load more...
Back to Home